Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate

By J. Stangier. Clinical Pharmacokinetics, 2008

700 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition) (2018, background): “A mild (CrCl 50–80 mL/min) to moderate (CrCl 30–49 mL/min) renal insufficiency increases the half-life up to 18 hours and 28 hours in severe renal insufficiency (CrCl 15–29 mL/min).(170,172,173)”
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). (2014, background): “Renal function, as measured by calculated CrCl, is no longer significant with age in the equation, although approximately 80% to 85% of dabigatran is excreted renally (6).”
Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity (2010, background): “Studies in healthy volunteers and patients show close linear correlation between ECT prolongation and plasma concentrations of DTIs, including melagatran, the active metabolite of ximelagatran, and dabigatran (9, 16, 18).”